Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Daniel V.T. Catenacci(University of Chicago), Yung‐Jue Bang(Seoul National University), Yoon‐Koo Kang(Ulsan College), Rosalyn A. Juergens(McMaster University), Daner Li(MacroGenics (United States)), Sun Jin Sym(Gachon University Gil Medical Center), Howard S. Höchster(Rutgers, The State University of New Jersey), Yeul Hong Kim(Seoul National University Bundang Hospital), Matthew Chau Hsien Ng(Duke-NUS Medical School), Aleksandra Franovic(Ondine Biopharma (United States)), Yee Chao(National Cancer Center), Johanna C. Bendell(Dana-Farber Cancer Institute), Keun-Wook Lee(Seoul National University Bundang Hospital), Keith L. Knutson(WinnMed), Eun‐Kee Song(Jeonbuk National University Hospital), Philip J. Gold, Cheng Ean Chee(National University Cancer Institute, Singapore), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Jill Lacy(Smilow Cancer Hospital), Se Hoon Park(Samsung Medical Center), Kristen A. Marrone(Johns Hopkins University), Ronan J. Kelly(Baylor University Medical Center), Sunnie S. Y. Kim(Princeton University), Jong Gwang Kim(Kyungpook National University Hospital), Thierry Alcindor(McGill University), A. Craig Lockhart(Washington University in St. Louis), Haeseong Park(Brigham and Women's Hospital), Sang Cheul Oh(Korea University), Jennifer Yen(Guardant (United States)), Peter C. Enzinger(Dana-Farber Cancer Institute), Jeffrey L. Nordstrom(MacroGenics (United States)), Hope E. Uronis(Duke Medical Center), Minori Koshiji Rosales(MacroGenics (United States)), Jan Davidson‐Moncada(MacroGenics (United States))
Cited by 190
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k